

## **Revolution Medicines to Participate in Upcoming Investor Conferences**

August 31, 2022

REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured speaker in fireside chats at the 2022 Wells Fargo Healthcare Conference and the H.C. Wainwright 24<sup>th</sup> Annual Global Investment Conference.

Details of these events are as follows:

• 2022 Wells Fargo Healthcare Conference

Conference Date: September 7-9, 2022 Fireside Chat Time/Date: 3:45 – 4:15 p.m. Eastern on Thursday, September 8, 2022 Format: In-person conference located at Encore Boston Harbor

• H.C. Wainwright 24<sup>th</sup> Annual Global Investment Conference Conference Date: September 12-14, 2022 Fireside Chat Time/Date: 7:00 a.m. Eastern on Monday, September 12, 2022 Format: Hybrid event (in-person and virtual); webcast available

A webcast of the H.C. Wainwright fireside chat can be accessed at: https://ir.revmed.com/events-and-presentations. An archived replay of the webcast will be available on the investors section of the company's website for at least 14 days following the event.

## About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RAS <sup>MULTI</sup>) and RMC-6291(KRAS<sup>G12C</sup>) are in clinical development. Additional RAS(ON) Inhibitors in development include RMC-9805 (KRAS<sup>G12D</sup>) and RMC-8839 (KRAS<sup>G13C</sup>), and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

Contacts: For Investors: Vida Strategic Partners Stephanie Diaz 415-675-7401 sdiaz@vidasp.com For Media: Vida Strategic Partners Tim Brons 415-675-7402 tbrons@vidasp.com